Amgen Inc. (AMGN)
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns
Key acquisitions since 2022 increased Amgen's rare disease pipeline and footprint in the market, with the company poised to benefit from the rare disease market's 10.35% CAGR up to 2037. A growing portfolio of biosimilar products will drive double-digit sales growth in the coming decade. The immense growth potential in both its rare disease and biosimilar portfolios is essential for Amgen to offset patent cliff headwinds.
What Makes Amgen (AMGN) a New Buy Stock
Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Medical Stocks Lagging Amgen (AMGN) This Year?
Here is how Amgen (AMGN) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen (AMGN) is a Top-Ranked Growth Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Amgen (AMGN) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest trading session, Amgen (AMGN) closed at $295.18, marking a -1.73% move from the previous day.
Amgen: A Defensive Biotech With Yield And Optionality
Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid, offering defensive characteristics, capital preservation, and yield over high-growth potential. The diversified product base and growing biosimilars segment reduce concentration and patent cliff risks, supporting Amgen's stability as a portfolio anchor. Biosimilars face execution, pricing, and demand risks, but continued strong growth could offset upcoming revenue losses from key patent expirations.
Amgen (AMGN) Advances While Market Declines: Some Information for Investors
Amgen (AMGN) closed the most recent trading day at $297, moving +1.38% from the previous trading session.
Amgen (AMGN) Outperforms Broader Market: What You Need to Know
The latest trading day saw Amgen (AMGN) settling at $296.85, representing a +2.18% change from its previous close.
Trading Rotation Kicks Off 2nd Half of 2025
Tech stocks lagged after a very strong first half of the year, while healthcare led the way.
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
